French Medical Journal Calls for Ban of Anti-Vomiting Drug
Domperidone (sold as Motilium, Motillium, Motinorm Costi and Nomit) was developed by Janssen Pharmaceuticals to relieve nausea and vomiting symptoms and increase the transit of food through the stomach and bowel.
The drug has also seen abundant use among those affected with Parkinson’s disease as the drug reduces gastrointestinal symptoms associated with the disease as well as nausea-related side effects caused by Parkinson’s disease treatments.
The drug has been available since the 1980s and has generated more than a dozen generic medications, but experts are now questioning the drug’s following a year-long study by the European Medicines Agency (EMA).
Domperidone Linked to Cardiac Problems and Death
According to the Connexion, Prescrire is alleging that the benefits of the drug are “too modest to justify the exposure to premature deaths” and stated that the drug may have contributed to between 25 and 120 deaths in France in 2012 alone.
While previous studies have linked domperidone to cardiac risks, the medical journal referenced studies by Canadian and Dutch teams which have demonstrated an increase in the frequency of sudden death among people exposed to domperidone.
The final study from the EMA is expected to be published in March. The European Medicines Agency previously flagged the dug for increased risk of sudden death in 2011.
Side Effects of Domperidone
The following adverse events have also been linked to domperidone:
- Chest pain
- Renal failure